BRIEF published on 06/10/2026 at 20:18, 13 days 23 hours ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 13 days 23 hours ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 13 days 23 hours ago Poxel nomme Yves Decadt comme nouveau Directeur Général Partenariats Stratégiques Biopharmaceutique Plan De Continuation Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 13 days 23 hours ago Poxel nomme Yves Decadt PDG pour faire progresser ses objectifs stratégiques Partenariats Stratégiques Biopharmaceutique Poxel Iméglimine Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 13 days 23 hours ago Informations privilégiées / Autres communiqués Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques. Continuité et ambition commerciale confirmée Partenariats Poxel PXL065 Iméglimine Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 13 days 23 hours ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 2 months 24 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 2 months 24 days ago Poxel cède le PXL770 à Scynexis pour une valeur potentielle de 196 millions de dollars Accord Financier Poxel PXL770 SCYNEXIS Polykystose Rénale
BRIEF published on 03/31/2026 at 13:12, 2 months 24 days ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 2 months 24 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
Published on 06/24/2026 at 14:45, 5 hours 14 minutes ago Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 5 hours 59 minutes ago GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 5 hours 59 minutes ago Adcore Announces Voting Results from Annual Shareholders Meeting
Published on 06/24/2026 at 13:05, 6 hours 54 minutes ago Faraday Copper Reports Drill Results Including Near-Surface Copper Mineralization in the American Eagle Area
Published on 06/24/2026 at 18:25, 1 hour 34 minutes ago Huawei Helps Global Carriers Monetize Tokens with Service-Network-Compute Integration
Published on 06/24/2026 at 18:25, 1 hour 34 minutes ago Annual General Meeting of Highlight Event and Entertainment AG
Published on 06/24/2026 at 18:05, 1 hour 54 minutes ago BOS GmbH & Co. KG: Admission of bonds to trading on the Luxembourg Stock Exchange
Published on 06/24/2026 at 19:00, 59 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 1 hour 59 minutes ago KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 2 hours 14 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
